| Autor: |
S. A. Bergstra, L. van Ouwerkerk, I. S. Nevins, J. A. van der Pol, G. S. Helmich, I. Hest, A. van Veen, R. Bos, Y. P. M. Goekoop-Ruiterman, H. E. Vonkeman, J. Bijsterbosch, P. H. P. de Jong, M. Güler-Yüksel, S. Böhringer, T. W. J. Huizinga, F. A. van Gaalen |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Trials, Vol 25, Iss 1, Pp 1-15 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1745-6215 |
| DOI: |
10.1186/s13063-024-08609-5 |
| Popis: |
Abstract Background Undifferentiated arthritis (UA) is a term used to describe patients with inflammatory arthritis that has not differentiated into a specific rheumatic disease. UA may be a pre-stage of rheumatoid arthritis (RA) or another inflammatory disease or remain undifferentiated, but a substantial proportion of patients may also achieve spontaneous remission. As UA may be an early presentation of RA, rheumatologists often start methotrexate (or another csDMARD) as early as possible. There are however very little data on the potential benefits of early DMARD treatment, and longitudinal data suggests that long-term outcomes such as physical functioning hardly improved in these patients in the past decades. In the I CEA trial, we investigate if it is beneficial to start early treatment with MTX or baricitinib, a more rapidly acting drug with a broader mechanism of action, compared to waiting for spontaneous remission with symptomatic therapy in patients with UA. Methods The I CEA is a multicenter single-blind (independent assessor) randomized clinical trial with a 3-month interventional and 9-month observational follow-up period. The study includes patients with early ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
